BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 24791791)

  • 1. [Effects of poly(ADP-ribose)polymerase inhibitor AG014699 combined with chemotherapy on the proliferation of triple-negative breast cancer cell line MDA-MB-231].
    Sun Y; Ding H; Li XQ; Li L
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2014 Apr; 36(2):135-9. PubMed ID: 24791791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells.
    Sun Y; Ding H; Liu X; Li X; Li L
    Tumour Biol; 2014 May; 35(5):4469-77. PubMed ID: 24420152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
    Daniel RA; Rozanska AL; Thomas HD; Mulligan EA; Drew Y; Castelbuono DJ; Hostomsky Z; Plummer ER; Boddy AV; Tweddle DA; Curtin NJ; Clifford SC
    Clin Cancer Res; 2009 Feb; 15(4):1241-9. PubMed ID: 19174487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
    Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
    Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
    Drew Y; Mulligan EA; Vong WT; Thomas HD; Kahn S; Kyle S; Mukhopadhyay A; Los G; Hostomsky Z; Plummer ER; Edmondson RJ; Curtin NJ
    J Natl Cancer Inst; 2011 Feb; 103(4):334-46. PubMed ID: 21183737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation.
    Xie Z; Zhou Y; Zhao W; Jiao H; Chen Y; Yang Y; Li Z
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4557-61. PubMed ID: 26342868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of PARP-1 exert inhibitory effects on the biological characteristics of hepatocellular carcinoma cells in vitro.
    Mao X; Du S; Yang Z; Zhang L; Peng X; Jiang N; Zhou H
    Mol Med Rep; 2017 Jul; 16(1):208-214. PubMed ID: 28498459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.
    Ali M; Kamjoo M; Thomas HD; Kyle S; Pavlovska I; Babur M; Telfer BA; Curtin NJ; Williams KJ
    Mol Cancer Ther; 2011 Dec; 10(12):2320-9. PubMed ID: 21926192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-targeting deoxyribonucleic acid-dependent protein kinase and poly(adenosine diphosphate-ribose) polymerase-1 promotes accelerated senescence of irradiated cancer cells.
    Azad A; Bukczynska P; Jackson S; Haupt Y; Cullinane C; McArthur GA; Solomon B
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):385-94. PubMed ID: 24411611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.
    Plummer R; Jones C; Middleton M; Wilson R; Evans J; Olsen A; Curtin N; Boddy A; McHugh P; Newell D; Harris A; Johnson P; Steinfeldt H; Dewji R; Wang D; Robson L; Calvert H
    Clin Cancer Res; 2008 Dec; 14(23):7917-23. PubMed ID: 19047122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of INPP4B gene transfection combined with PARP inhibitor on castration therapy-resistant prostate cancer cell line, PC3.
    Ding H; Sun Y; Hou Y; Li L
    Urol Oncol; 2014 Jul; 32(5):720-6. PubMed ID: 24837011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?
    Ali M; Telfer BA; McCrudden C; O'Rourke M; Thomas HD; Kamjoo M; Kyle S; Robson T; Shaw C; Hirst DG; Curtin NJ; Williams KJ
    Clin Cancer Res; 2009 Oct; 15(19):6106-12. PubMed ID: 19789326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gamma secretase inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells.
    Li ZL; Chen C; Yang Y; Wang C; Yang T; Yang X; Liu SC
    Int J Clin Exp Pathol; 2015; 8(5):4378-87. PubMed ID: 26191129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Apoptosis of MDA-MB-231 cells induced by berberine alpha-hydroxy beta-decanoylethyl sulfonate].
    Tang JW; Lin J
    Yao Xue Xue Bao; 2014 Jan; 49(1):131-5. PubMed ID: 24783518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib.
    Maiello MR; D'Alessio A; De Luca A; Carotenuto A; Rachiglio AM; Napolitano M; Cito L; Guzzo A; Normanno N
    Breast Cancer Res Treat; 2007 May; 102(3):275-82. PubMed ID: 17004112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-treatment of breast cancer cells with pharmacologic doses of 2-deoxy-D-glucose and metformin: Starving tumors.
    Wokoun U; Hellriegel M; Emons G; Gründker C
    Oncol Rep; 2017 Apr; 37(4):2418-2424. PubMed ID: 28350075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
    Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
    Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells.
    Andreidesz K; Koszegi B; Kovacs D; Bagone Vantus V; Gallyas F; Kovacs K
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of amentoflavone as a potent highly selective PARP-1 inhibitor and its potentiation on carboplatin in human non-small cell lung cancer.
    Hu XL; Feng JH; Pham TA; Ma HY; Ma MX; Song R; Shen W; Xiong F; Zhang XQ; Ye WC; Wang H
    Phytomedicine; 2018 Nov; 50():88-98. PubMed ID: 30466996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.